Host: |
HEK293 |
Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human Carboxypeptidase A4-protein was developed from hek293. For use in research applications. |
Conjugation: |
Unconjugated |
Formulation: |
Lyophilised from 0.2 Mu m filtered PBS solution, pH7.2, 5% Trehalose. |
Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
Storage Instruction: |
Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C to-70°C for 1 year. Avoid repeated freeze/thaw cycles. NA |
Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
Immunoreactivity: |
The activity was tested by the ability to cleave a fluorogenic substrate Ac-Phe-Thiaphe-OH in the presence of 5, 5 Dithio-bis. The specific activity was measured to be 3 nmole/ug/min NA |
Gene Symbol: |
CPA4 |
Gene ID: |
51200 |
Uniprot ID: |
CBPA4_HUMAN |
Immunogen Region: |
GLY17-TYR421 |
Immunogen: |
Optimized DNA sequence encoding Human Carboxypeptidase A4 (GLY17-TYR421) preprotein including a C-terminal His tag was expressed in HEK293 cells. NA |
Tissue Specificity | Fetal expression in the adrenal gland, brain, heart, intestine, kidney, liver and lung. Except for fetal brain that shows no imprinting, expression was found preferentially from the maternal allele. |
Function | Metalloprotease that could be involved in the histone hyperacetylation pathway. Releases a C-terminal amino acid, with preference for -Phe, -Leu, -Ile, -Met, -Tyr and -Val. |
Protein Name | Carboxypeptidase A4Carboxypeptidase A3 |
Cellular Localisation | Secreted |
Alternative Protein Names | Carboxypeptidase A4 proteinCarboxypeptidase A3 proteinCPA4 proteinCPA3 proteinUNQ694 proteinPRO1339 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance